Advertisement
Singapore markets closed
  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     
  • Nikkei

    39,583.08
    +241.54 (+0.61%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     
  • Bitcoin USD

    60,703.46
    -995.87 (-1.61%)
     
  • CMC Crypto 200

    1,265.97
    -17.86 (-1.39%)
     
  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     
  • Dow

    39,118.86
    -45.20 (-0.12%)
     
  • Nasdaq

    17,732.60
    -126.08 (-0.71%)
     
  • Gold

    2,336.90
    +0.30 (+0.01%)
     
  • Crude Oil

    81.46
    -0.28 (-0.34%)
     
  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     
  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     
  • Jakarta Composite Index

    7,063.58
    +95.63 (+1.37%)
     
  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment

FILE PHOTO: An AstraZeneca logo is pictured in Brussels

(Reuters) - China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said on Wednesday.

AstraZeneca said the approval by China's National Medical Products Administration (NMPA) was based on trials which showed that patients given the combination treatment lived without the disease getting worse longer than those given just Tagrisso.

The median progression-free survival of patients treated with Tagrisso and chemotherapy was 25.5 months, 8.8 months more than those treated with just Tagrisso.

(Reporting by Chandini Monnappa in Bengaluru; Editing by Savio D'Souza)